Cancer Research The Future of Cancer Research: Science and Patient Impact Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4148-4154, August 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, H.-R. C.
Right arrow Articles by Raz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H.-R. C.
Right arrow Articles by Raz, A.
[Cancer Research 59, 4148-4154, August 15, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells1

Hyeong-Reh Choi Kim2, Huei-Min Lin, Hector Biliran and Avraham Raz

Department of Pathology [H-R. C. K., H-M. L., H. B., A. R.], Breast Cancer Program [H-R. C. K.], Tumor Progression and Metastasis Program [A. R.], Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, Michigan 48201


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Galectin-3 is a member of a growing family of animal ß-galactoside-binding proteins shown to be involved in cell growth, differentiation, apoptosis resistance, and tumor progression. In the present study, we investigated whether galectin-3 can protect against apoptosis induced by the loss of cell anchorage (anoikis). Because studies suggest that cellular sensitivity to anoikis is associated with cell cycle regulation, we examined the role of galectin-3 on cell cycle regulation. Although BT549 cells (human breast epithelial cells) undergo anoikis, galectin-3-overexpressing BT549 cells respond to the loss of cell adhesion by inducing G1 arrest without detectable cell death. Galectin-3-mediated G1 arrest involves down-regulation of G1-S cyclin levels (cyclin E and cyclin A) and up-regulation of their inhibitory protein levels (p21WAF1/CIP1 and p27KIP1). After the loss of cell anchorage, Rb protein becomes hypophosphorylated in galectin-3-overexpressing cells, as predicted from the flow cytometric analysis and immunoblot analysis of cyclins and their inhibitors. Interestingly, galectin-3 induces cyclin D1 expression (an early G1 cyclin) and its associated kinase activity in the absence of cell anchorage. On the basis of these results, we propose that galectin-3 inhibition of anoikis involves cell cycle arrest at an anoikis-insensitive point (late G1) through modulation of gene expression and activities of cell cycle regulators. The present study suggests that galectin-3 may be a critical determinant for anchorage-independent cell survival of disseminating cancer cells in the circulation during metastasis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell-matrix interactions regulate many cellular responses including gene expression, differentiation, and cell survival (1, 2, 3) . The ECM3 is a complex network of macromolecules that is composed of collagens, laminin, fibronectin, proteoglycans, and many soluble molecules including growth factors (4) . The ECM of both the prostate and the lactating mammary gland undergo drastic involution upon removal of the appropriate trophic hormones (5) . Because hormone ablation induces secretion of ECM-degrading enzymes that disrupt the interaction of epithelial cells with the ECM, it was hypothesized that the loss of cell-matrix interactions induces anoikis, a specific form of apoptosis (6) .

Integrins are heterodimeric cell surface receptors that mediate cell adhesion to ECM (7 , 8) . Neutralizing antibodies against integrins induce cell detachment, followed by anoikis in epithelial cells, suggesting a role for integrin signaling in the regulation of anoikis (9) . Integrin and growth factor receptor signals coregulate the turnover of phospholipids and play nonredundant roles in cell cycle progression (10 , 11) . Growth factor signaling triggers cell cycle progression from G0 to G1, whereas cell adhesion mediates the transition through the restriction point contained in late G1. Cyclin D1 expression and the activities of cyclin E-associated kinases, the functions of which are critical for G1-S transition, are shown to depend on cell adhesion (10 , 11) . This may explain why nonadherent cells fail to transit the cell cycle. Although normal epithelial cells require cell-extracellular matrix interactions for cell survival and growth, invasive and motile mesenchymal cells survive without these interactions and become arrested at the G1 stage of the cell cycle (6) . This shows that anoikis sensitivity is associated with cell cycle regulation.

Because retaining anchorage-independent viability of disseminating cells in the circulation is critical for tumor cell metastasis, we investigated the role of galectin-3 in the cellular response to the loss of cell contact. The human galectin-3 is a Mr 31,000 glycoprotein that belongs to a family of galactoside-binding proteins that are highly expressed in many human tumor cells including breast carcinoma cells (12, 13, 14, 15, 16) . Structurally, galectin-3 is composed of two distinct domains: an NH2-terminal of 12 amino acids preceding a collagen-like sequence, and a globular COOH-terminal domain containing the carbohydrate-binding site (12 , 17) . Although galectin-3 is not a bcl-2 family member, it contains the same four amino acid motif (NWGR) conserved in the BH1 domain of the bcl-2 gene family. This motif is critical for bcl-2 antiapoptotic activity (18) . Consistently, we and others have found that galectin-3 is a novel antiapoptotic gene product (19 , 20) and showed that substitution of the Gly182 residue with Ala in the NWGR motif of galectin-3 abrogates its antiapoptotic activity (19) . Thus, similar to the bcl-2 protein (18) , the NWGR motif appears to be critical for the antiapoptotic function of galectin-3.

Although the exact function of galectin-3 is still debatable, galectin-3 expression has been associated with transforming and metastatic potentials (12, 13, 14, 15, 16) . Ectopic expression of galectin-3 in the human breast cancer cell line BT549 resulted in the acquisition of a potent tumorigenic phenotype in nude mice (15 , 21) . We questioned whether oncogenic activity of galectin-3 involves anti-anoikis activity. Because cell cycle regulation is associated with anoikis (6 , 9 , 11) , we have investigated the roles of galectin-3 on cell cycle regulation during anoikis. We report that galectin-3 prevents anoikis in human breast epithelial cells. We also present data that suggest that galectin-3-mediated inhibition of anoikis may result from its ability to induce cell cycle arrest at late G1 through expression modulation of cyclins and their inhibitors.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Line and Monolayer Culture Condition.
The human breast cancer cell line BT549 was obtained from Dr. E. W. Thompson (Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC). Galectin-3-transfected BT549 cell clones were established previously by introducing an expression vector containing human galectin-3 cDNA in either the sense or the antisense orientation into BT549 parental cells (19 , 21) . Galectin-3 antiapoptotic activity was characterized previously using three independent, galectin-3-expressing BT549 clones (11811, 11913, and 11914; Ref. 19 ). In the present study, we have also used these three clones. We present data mostly obtained using clone 11914 to avoid redundancy. Hereafter, galectin-3-transfected BT549 clone 11914, antisense galectin-3-transfected BT549 clone 41421, and neo-resistant control vector-transfected BT549 (19) are referred to as BT549-Galwt, BT549-GalAS, and BT549neo, respectively. The mutant galectin-3-expressing BT549 in which the Gly182 of the NWGR motif was substituted to Ala (Ref. 19 ) is referred as to BT549-Galm. Cells on tissue culture dishes (Sarstedt, Newton, NC) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 0.5 µg/ml fungizone in a 95% air and 5% C02 incubator at 37°C.

Induction of Anoikis (Suspension Culture).
PolyHEMA (purchased from Aldrich Chemical Co., Madison, WI) was solubilized in methanol (50 mg/ml) and diluted in ethanol to a final concentration of 10 mg/ml. To prepare polyHEMA-coated dishes, 4 ml of polyHEMA solution were placed onto 100-mm Petri dishes and dried in a tissue culture hood. The polyHEMA coating was repeated twice, followed by three washes with PBS. Anoikis was induced by culturing 1.5 x 106 cells on polyHEMA- coated 100-mm dishes in a humidified 5% CO2 incubator with RPMI 1640 supplemented as described above.

Determination of Cell Cycle Distribution.
The percentage of cells in each cell cycle phase was determined by flow cytometry (PAS-II; Partec AG, Münster, Germany). Cells grown for 24 h on monolayer or in suspension (polyHEMA-coated dishes) were trypsinized, suspended in culture medium, centrifuged at 150 x g for 5 min, and fixed with 70% ethanol. The fixed cells were centrifuged, and the cell pellet was resuspended in Hoechst staining solution at a concentration of 1 x 106 cells/ml and incubated for 3 min at room temperature. The staining solution consisted of 3 µg/ml Hoechst 33258 (Sigma Chemical Co., St. Louis, MO) in Tris buffer (2 mM MgCl2, 0.1% Triton X-100, 154 mM NaCl, and 100 mM Tris, pH 7.5). The stained cells (30,000) were analyzed by flow cytometry. Optical filtration included a UG-1 excitation filter, a 420-nm dichroic filter, and 435-nm long pass emission filter. Single-channel data were acquired and subsequently analyzed with a computer program (Phoenix Flow Systems, San Diego, CA).

SDS-PAGE and Immunoblot Analysis.
Protein extracts were prepared by lysing 1 x 106 cells with 50 µl of 2x SDS sample buffer, and protein concentration was measured using BCA protein assay reagents (Pierce, Rockford, IL). Extracts were boiled for 10 min, chilled on ice, and subjected to SDS-PAGE analysis, followed by electrophoretic transfer to a nitrocellulose membrane. Expression levels were measured using the following antibodies: anti-PARP (C-2–10; Biomol Research Laboratory, Plymouth Meeting, PA), anti-galectin-3 (American Type Culture Collection, Rockville, MD), anti-human bcl-2 (DAKO A/S, Denmark), anti-cyclin D1 (Ab2; Oncogene Research, Cambridge, MA), anti-cyclin E (HE67; PharMingen, San Diego, CA), anti-cyclin A (BF683; Santa Cruz Biotechnolgy, Santa Cruz, CA), anti-p15 (C-20; Santa Cruz Biotechnology), anti-p21WAF1/CIP1 (Cal Biochem, San Diego, CA), anti-p27KIP1 (M-197; Santa Cruz Biotechnology), and anti-Rb (SC4112; Santa Cruz Biotechnology).

Cyclin D1 and Cyclin E-associated Kinase Assay.
Extracts were prepared by lysing the cells in ice-cold buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 25 mM NaF, 1 mM sodium vanadate, 1 mM EDTA, 2 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 25 mM NaF, 0.5% NP40, and 10 µg/ml leupeptin and aprotinin. After removing the precipitate by centrifugation at 14,000 rpm for 15 min at 4°C, the cyclin D1 and cyclin E complexes were collected using the anti-cyclin D1 or anti-cyclin E antibodies and protein G-Sepharose. The complex was washed three times with 1.0 ml of washing buffer (1% deoxycholate, 0.5% Tween 20, and 50 mM Tris-HCl, pH 7.5) and once with 1 ml of 50 mM Tris (pH 7.5) and 10 mM MgCl2. Kinase activity of the cyclin D1-immune complex was measured using 2.5 µM GST-pRb protein (purchased from Santa Cruz Biotechnology), and cyclin E-complex using histone H1 protein (Boehringer Manheim, Indianapolis, IN) as substrate in 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM DTT, 0.5 mM NaF, 0.1 mM sodium orthovandate, 5 µg/ml leupeptin, and [{gamma}-32P]ATP (0.01–0.3 nCi/pmol). After kinase reaction at 30°C for 30 min, samples were mixed with 2x SDS buffer and subjected to SDS-PAGE analysis. [{gamma}-32P]ATP-labeled Rb and histone H1 proteins were visualized by autoradiography.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Galectin-3 Inhibits Apoptosis and Induces G1 Arrest after Loss of Cell-Matrix Interactions.
Anoikis was induced by culturing cells in suspension using polyHEMA-coated tissue culture dishes, which prevent cell adhesion, as described in "Materials and Methods." To determine whether galectin-3 inhibits anoikis, we examined the apoptosis-specific cleavage of PARP, an early event in apoptosis resulting from the activation of interleukin 1ß-converting enzyme (caspase)/Ced-3 family members (22) . As shown in Fig. 1ACitation , proteolytic cleavage of PARP was readily detected in the parental control and BT549-GalAS cells, whereas it was significantly inhibited in BT549-Galwt cells, even after 3 days in suspension culture. Galectin-3 inhibition of anoikis was also confirmed by nuclear morphological analysis. The nuclei were stained using Hoechst 33258 after 48 h in suspension culture, as described previously (23) . The parental control and the BT549-GalAS cells showed fragmented nuclei that were consistent with nuclear morphological changes in other apoptotic cells (23) . In contrast, no significant changes in nuclear morphology could be observed in BT549-Galwt cells (data not shown).



View larger version (47K):
[in this window]
[in a new window]
  		Fig. 1. Galectin-3, but not mutant galectin-3, inhibits anoikis in breast epithelial cells. A, immunoblot analysis of PARP protein using cell lysates prepared from BT549-Galwt (Lanes 1–3), BT549-GalAS (Lanes 7–9), and control BT549 cells (Lanes 4–6). Twenty µg of protein samples were prepared at 24 h (Lanes 1, 4, and 7), 48 h (Lanes 2, 5, and 8), or 72 h (Lanes 3, 6, and 9) after plating on polyHEMA-coated dishes. B and C, immunoblot analysis of PARP protein using cell lysate (5 µg for B and 10 µg for C) prepared from control BT549 (Lane 1 in B), BT549-Galwt (Lane 2 in B), and BT549-GalAS (Lane 3 in B), BT549-neo (Lane 1 in C), two individual clones of BT549-Galm (clones A3 and A5 in Lanes 2 and 3 in C, respectively) after 24 h of suspension culture.

 
Because cell cycle regulation is associated with sensitivity to anoikis (6 , 9 , 11) , flow cytometric DNA analysis was performed to determine the cell cycle phase distribution of cells grown on monolayer or in suspension for 24 h. In exponentially growing monolayer cultures, the percentage of BT549neo in G1 phase was 46.8%, whereas only 26.2% of BT549-Galwt was in the G1 phase (Fig. 2, A and C)Citation . In suspension culture of BT549neo, the G1 population decreased to 25.4%, and the sub-G1 population increased from 7 to 25.4% (Fig. 2, A and B)Citation . Flow cytometric DNA analysis, morphological analysis, and PARP cleavage showed that BT549 cells underwent apoptotic cell death in response to the loss of cell-substrate interactions. In contrast, no sub-G1 population of BT549-Galwt was detected, regardless of the state of cell-substrate interactions, whereas a dramatic increase in the G1 population (from 26.2 to 78.6%) was detected in BT549-Galwt in the absence of cell-substrate interactions (Fig. 2, C and D)Citation . These results show that galectin-3 overexpression renders BT549 cells able to respond to the loss of cell- ECM contact by growth arrest at G1 without detectable apoptotic cell death.



View larger version (38K):
[in this window]
[in a new window]
  		Fig. 2. Galectin-3 induces G1 arrest after the loss of cell-matrix interactions. Flow cytometric cell cycle histograms of BT549neo (A and B) and BT549-Galwt (C and D). The same numbers of cells were grown for 24 h on monolayer (A and C) or in suspension (B and D). The proportions of cells in each cell cycle phase are presented.

 
Galectin-3 Down-Regulates Expression of Late G1 and S phase Cyclins and Up-Regulates CDKIs.
After the loss of cell-substrate contacts, the G1 population increase of BT549-Galwt was accompanied by a 6.7-fold decrease in the proportion of cells in S phase, suggesting that galectin-3 overexpression inhibits G1 to S phase progression. Cyclin E-associated kinases are activated late in G1 phase, and their activities are thought to be critical for the progression to S phase (24, 25, 26) . Cyclin A-associated kinase activities are then activated concomitantly with the onset of S phase and involved in maintenance of S phase (27, 28, 29) . Therefore, we sought to determine whether expression of these cyclins is modulated by galectin-3 when cultured on monolayer or in suspension. As shown in Fig. 3Citation , expression of cyclin E was down-regulated by galectin-3, especially after the loss of cell-substrate interactions. In monolayer culture, cyclin A expression was up-regulated by galectin-3, in agreement with a proportional increase in BT549-Galwt in S phase compared with BT549neo. However, cyclin A expression was significantly down-regulated in BT549-Galwt upon cell detachment, whereas the loss of cell-substrate interactions had no effect on cyclin A expression in BT549neo. These data (Fig. 3, A and B)Citation suggest that galectin-3-mediated G1 arrest in the absence of cell anchorage involves drastic down-regulation of cyclin E and cyclin A expression.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 3. Galectin-3 modulates expression of cyclins and their inhibitor proteins. Immunoblot analyses of galectin-3, cyclin A, cyclin D1 (A); cyclin E, ß-actin (B); and p27, p21, and p15 (C). Protein samples were prepared from BT549-Galwt, BT549-Galm clone A5, BT549-Galm clone A3, or BT549-neo as indicated above each panel. Cells were cultured for 24 h on polyHEMA-coated plates (suspension) or on regular tissue culture plates (monolayer).

 
Kinase activities of cyclin E and cyclin A complexes are regulated by CDKIs, including p21WAF1/CIP1 and p27KIP1 (30, 31, 32) . Therefore, we also examined the effects of galectin-3 overexpression on CDKI expression with regard to cell-matrix interactions. As shown in Fig. 3CCitation , expression of both p21WAF1/CIP1 and p27KIP1 was up-regulated by galectin-3 and further increased after cell-matrix detachment (Fig. 3C)Citation . Galectin-3 modulation of cyclin E and cyclin A as well as their inhibitors in suspension culture is consistent with cell cycle arrest at mid-G1 as shown in flow cytometric analysis (Fig. 2D)Citation . However, the immunoblot analysis showed that galectin-3 down-regulated cyclin E and slightly up-regulated p21WAF1/CIP1 and p27KIP1, even in proliferating monolayer culture. To assess the functional significance of changes in expression of cyclin E and its inhibitors, we measured cyclin E-associated kinase activity in vitro using histone H1 as substrate. Surprisingly, cyclin E-associated kinase activity was not drastically altered by galectin-3 on monolayer culture (Fig. 4A)Citation , whereas its activity is significantly down-regulated by galectin-3 in suspension culture. The cyclin E-associated kinase activity agrees with G1-S transition in monolayer culture of BT549-Galwt and G1 arrest in suspension culture. In monolayer culture, it is not clear how cyclin E-associated kinases are activated in BT549-Galwt cells with low levels of cyclin E protein as efficiently as in BT549neo (see "Discussion").



View larger version (43K):
[in this window]
[in a new window]
  		Fig. 4. Galectin-3 down-regulates cyclin E-associated kinase activity, and the Rb protein becomes hypophosphorylated in BT549-Galwt cells after the loss of cell-matrix interactions. A, cyclin E-complexes were immunoprecipitated from the cell extracts of BT549-neo (Lanes 1 and 4), BT549-Galwt (Lanes 2 and 5), and BT549-Galm clone 5 (Lanes 3 and 6) cultured in monolayer (Lanes 1–3) or in suspension (Lanes 4–6) for 24 h. Kinase activity of the complexes was measured in the presence of [{gamma}-32P]ATP using histone H1 protein as substrate. Kinase activities were quantitated and normalized to that in monolayer culture of BT549-neo (top panel). B, immunoblot analysis of Rb protein using cell lysates prepared from BT549neo, BT549-Galwt clone 11914, BT549-Galwt clone 11913, and BT549-Galwt clone 11811. Cells were cultured for 24 h on polyHEMA-coated plates (S) or on regular tissue culture plates (M). The hyperphosphorylated Rb (ppRb) and hypophosphorylated Rb (pRb) are shown. *, nonspecific bands recognized by anti-Rb antibodies (purchased from Santa Cruz Biotechnology).

 
To determine whether the in vivo kinase activities of cyclin complexes were modulated by galectin-3, we examined the status of Rb phosphorylation in monolayer or suspension cultures of three independent galectin-3-overexpressing BT549 clones. The Rb protein is hypophosphorylated in G0 and early G1 phases and binds to a series of cellular proteins including E2F transcription factor. Rb protein becomes hyperphosphorylated by D-type cyclin-dependent kinases and further phosphorylated by cyclin E- and A-dependent kinases (33 , 34) . The hyperphosphorylated pRb becomes inactive and is no longer capable of binding to its interacting molecules such as E2F. This hyperphosphorylated state is maintained through S, G2, and most of M phases. As shown in Fig. 4BCitation , hyperphosphorylated Rb was dominant in three clones, indicating that most of the cells are in S to M phases when cultured on monolayer (also see Fig. 2CCitation ). In contrast, only hypophosphorylated Rb was detected in suspension cultures of BT549-Galwt clones, showing that these cells fail to enter S phase, and cdk activities are down-regulated, as predicted by flow cytometric analysis and the immunoblot assay (Figs. 2Citation and 3Citation ). It should be noted that the Rb protein in the control cells was barely detectable, so the phosphorylation status of Rb protein in BT549neo was not determined.

Galectin-3 Up-Regulation of Cyclin D1 Is Independent of Cell Adhesion.
Recent studies showed that cell cycle progression is coregulated by growth factors and cell anchorage. Expression of the D-type cyclins, early G1 cyclins, requires cell adhesion (10 , 11) . To examine whether galectin-3 modulates the expression of the D-type cyclins, immunoblot analysis of cyclin Ds was performed. As shown in Fig. 3ACitation , cyclin D1 expression was induced by galectin-3 when cultured on monolayer. Interestingly, galectin-3 up-regulation of cyclin D1 expression was further enhanced in suspension cultures. In BT549 cells, neither cyclin D2 nor D3 was detected, irrespective of galectin-3 expression levels (data not shown). This suggests that galectin-3 up-regulates cyclin D1 expression independently of cell-substrate interactions.

The D-type cyclins are often inhibited by a family of inhibitors including p15INK4B, p16INK4A, and p19INK4D (35) . When the levels of these inhibitors were examined in BT549 cells, neither p16INK4A nor p19INK4D was detectable, and expression of p15INK4B was not significantly altered by galectin-3, regardless of cell adhesion (Fig. 3C)Citation . We next questioned whether galectin-3 induction of cyclin D1 expression lead to increased kinase activity. We examined whether cyclin D1 in BT549-Galwt cells was complexed to its functional partners (CDKs). The cyclin D1 complex was immunoprecipitated, and its associated kinase activity was measured using purified GST-pRb fusion protein as substrate. The Rb fusion proteins of Mr 46,000 were more efficiently phosphorylated by cyclin D1-associated kinases in BT549-Galwt cell lysates compared with those in BT549-neo in the absence of cell anchorage (Fig. 5)Citation . Although in vitro kinase assay showed that galectin-3 induction of cyclin D1 lead to activation of cyclin D1-associated kinases, the phosphorylated form of Rb was not detected in BT549-Galwt suspension culture (Fig. 4B)Citation . This is in agreement with previous reports that maintenance of hyperphosphorylation of Rb in vivo requires cyclin E and cyclin A-dependent kinase activities (33 , 34) .



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 5. Galectin-3 induces cyclin D1-associated kinase activity in the absence of cell anchorage. Cyclin D1 complexes were immunoprecipitated from the cell extracts of BT549-neo, BT549-Galwt, and BT549-Galm clone 5 (GalA5) cultured on polyHEMA-coated plates for 24 h. Kinase activity of the complexes was measured in the presence of [{gamma}-32P]ATP using purified GST-pRb fusion protein as a substrate. Radioactivity incorporated into GST-pRb fusion protein was determined by scintillation counting. Kinase activities in BT549-Galwt and BT549-Galm were normalized to that in BT549-neo.

 
The NWGR Motif Is Essential for Galectin-3 Anti-Anoikis Activity and Induction of Cell Cycle Arrest.
The significance of the NWGR motif for galectin-3 regulation of anoikis was evaluated using a galectin-3 mutant in which the Gly182 of the NWGR motif was substituted to Ala (Ref. 19 ; Fig. 6Citation ). Immunoblot analysis ensured that the mutant and wild-type galectin-3 proteins were stably expressed after the loss of cell-substrate contact (Fig. 3A)Citation . To explore whether mutant galectin-3 prevents anoikis, BT549-neo, BT549-Galwt and BT549-Gal m cells were cultured on polyHEMA-coated dishes for 24 h. Unlike in BT549-Galwt cells, apoptosis-specific cleavage of PARP protein occurred in both BT549-Galm cells and control cells (Fig. 1, B and C)Citation .



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 6. The NWGR motif in bcl-2 and galectin-3. The topologies of the human bcl-2 protein (adapted from Ref. 39 ) and galectin-3 protein are depicted. Both bcl-2 and galectin-3 contain a short NH2-terminal amino acid sequence that does not share homology among their family members.

 
We next examined the significance of the NWGR motif of galectin-3 for cell cycle regulation after loss of cell-substrate interactions. As shown in Fig. 3Citation , mutant galectin-3 failed to modulate expression of cyclin D1, cyclin E, cyclin A, p21WAF1/CIP1, and p27KIP1. In addition, in vitro kinase assay of the cyclin D1 and cyclin E complexes showed that a substitution of Gly182 to Ala in the NWGR motif of galectin-3 abolished its ability to modulate kinase activity of the cyclin D1 and cyclin E complexes after ECM detachment (Fig. 5)Citation . These results reemphasize that the integrity of the NWGR motif in the BH-1-like domain of galectin-3 is a prerequisite for its antiapoptotic activity as well as its ability to modulate expression of cell cycle regulators.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Although survival of "stationary" epithelial cells depends on cell-cell and cell-matrix interactions, invasive and motile mesenchymal cells survive without these interactions (36) . Cancer cells often acquire a "fibroblast-like" phenotype and become invasive. The present study showed that galectin-3 overexpression renders breast epithelial cells (BT549) able to respond to the loss of cell-ECM contact by growth arrest at G1 without detectable apoptotic cell death (anoikis), which resembles the response of fibroblast to loss of cell-ECM contact. Acquisition of anti-anoikis activity may be critical for anchorage-independent cancer cell survival in circulation during metastasis and might explain why galectin-3 expression is enhanced in some tumors with malignant phenotypes (12, 13, 14, 15, 16) . A key step in the apoptosis cascade is the activation of members of the interleukin-1ß converting enzyme/Ced-3 family (caspases; Ref. 37 ). This commitment step appears to be regulated by the Ced-9/bcl-2 family (37, 38, 39) . Our study clearly suggests the existence of a non-bcl-2 family member that regulates caspase-mediated apoptosis. Like the bcl-2 family, the galectin-3 family includes both proapoptotic and antiapoptotic members. Galectin-1 and galectin-9 are reported to play a role in the thymocyte-epithelial interactions and induce apoptosis of activated T lymphocytes (40, 41, 42, 43) . These studies and ours suggest that some members of the galectin family are novel regulators of apoptosis. It is noted that among galectin family members, only galectin-3 has the NWGR motif present in the BH1 domain of the bcl-2 gene family. Galectin-3 may interact with apoptosis-regulating molecules through the NWGR motif and replace bcl-2 activity.

The present study suggests that galectin-3 regulates the cell cycle through modulation of the cell cycle regulating gene expression. Galectin-3 up-regulates cyclin A expression, in agreement with an increase in BT549-Galwt in S phase compared with BT549neo. This is consistent with a recent report that the cellular expression of galectin-3 is proliferation dependent (44) . Galectin-3 does not alter cyclin E-associated kinase activity, although it down-regulates cyclin E protein expression in monolayer culture. The question is then how cyclin E-associated kinases are efficiently activated in these cells. Many isoforms of cyclin E are detected in breast cancer cells, and activities of these isoforms appear to be regulated by different mechanisms (45) . It should be noted that although galectin-3 down-regulates the major cyclin E protein, the lower molecular weight cyclin E protein was induced by galectin-3 in monolayer culture (Fig. 3B)Citation . Galectin-3-induced low molecular weight cyclin E isoform may be efficiently activated in monolayer culture. Or, galectin-3 up-regulation of cyclin D1 may be critical for efficient activation of cyclin E. Cyclin E-associated kinase was previously suggested to be active after it is phosphorylated by cyclin D1-associated kinase (46) . Lastly, galectin-3-induced p21WAF1/CIP1 and p27KIP1 may regulate cyclin E-associated kinase activities in a bidirectional manner. It was shown previously that the low levels of p21WAF1/CIP1 and p27KIP1 promote the assembly of active kinase complexes, whereas at higher concentrations, they inhibit activity (47) . Thus, it is possible that galectin-3-induced p21WAF1/CIP1 and p27KIP1 in monolayer culture may function as adaptor proteins of cyclin E complexes, which are critical for G1-S transition, whereas further induction in suspension culture results in inhibition of kinase activity.

Cyclin D1 overexpression has been associated with a poor prognosis (48, 49, 50, 51, 52) , dysregulation of the cell cycle, increased cell proliferation, increased EGF receptor expression, and p53 abnormalities in a transgenic model (53) . Cyclin D1 expression was shown to depend on adhesion in epithelial cells. Interestingly, galectin-3 up-regulates cyclin D1 expression independent of anchorage. It is not clear whether galectin-3 induction of cyclin D1 is associated with anti-anoikis activity of galectin-3 and/or with its oncogenic activity. Mounting evidence suggests that apoptosis regulation is tightly linked to regulation of the cell cycle. Although apoptosis can be induced at any point of the cell cycle, sensitivity of apoptosis greatly differs, depending on cell cycle points. Our study suggests that galectin-3 inhibition of anoikis may be related to its ability to regulate critical decision points between cell cycle progression and induction of apoptosis. Galectin-3 induction of cyclin D1-associated kinase activity may help cells pass the apoptosis-sensitive point in early G1. Similarly, galectin-3 down-regulation of cyclin E and cyclin A expression may be involved in cell cycle arrest at an anoikis-resistant point as summarized in Fig. 7Citation .



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 7. Model for galectin-3 regulation of the cell cycle and anoikis. Effects of galectin-3 overexpression on cell cycle regulation with or without cell contacts. Arrows, effects of galectin-3 overexpression on expression and/or activity of G1-S cyclins and their inhibitors. Galectin-3 induces expression/activity of cyclin D1 and cyclin A in monolayer culture, while it down-regulates cyclin E expression without affecting its associated kinase activity. After the loss of cell contacts, galectin-3 further induces cyclin D1 expression/activity and down-regulates cyclin E and cyclin A, resulting in G1 arrest without detectable apoptosis.

 
At present, it remains unclear how galectin-3 regulates expression of the cyclins and their inhibitors. Galectin-3 was shown to be a nuclear matrix protein that binds to RNA and single-stranded DNA (54) and identified as a splicing factor in cell-free splicing assay (55) . Nuclear galectin-3 may directly modulate gene expression through regulation of transcription and/or mRNA splicing. Or, cytoplasmic galectin-3 may modulate the activity of signaling molecules (e.g., kinases, phosphatases, and proteinases), which, in turn, transduce signals to regulate a set of gene expression. Galectin-3-mediated changes in the levels of the cyclins and their inhibitors may result from changes in gene expression of the adhesion-related genes. Cell adhesion transduces biochemical signaling, including focal adhesion kinase activation that is critical for anoikis regulation as well as cell cycle transition (7 , 56, 57, 58) . Whether cell cycle regulating genes are primary or secondary effects of galectin-3 overexpression, the present study showed that galectin-3 inhibition of anoikis is associated with cell cycle regulation. However, it remains to be fully investigated whether cell cycle regulation is a prerequisite for galectin-3 regulation of anoikis.


   ACKNOWLEDGMENTS
 
We thank Dr. Erik Thompson of the Lombardi Cancer Center for the gift of the BT-549 parental cells, Dr. Yong J. Lee for flow cytometric analysis, and Mary Ann Krug for preparation of the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by Grants CA64139 from the NIH/National Cancer Institute and by DAMD17-96-1-6181 from the United States Army (to H-R. C. K.) and CA46120 from the NIH/National Cancer Institute (to A. R.). Back

2 To whom requests for reprints should be addressed, at Department of Pathology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI 48201. Phone: (313) 577-2407 or 0193; Fax: (313) 577-0057; E-mail: hrckim{at}med.wayne.edu Back

3 The abbreviations used are: ECM, extracellular matrix; AS, anti-sense; CDK, cyclin-dependent kinase; CDKI, CDK inhibitor; GST, glutathione S-transferase; PARP, poly(ADP-ribose) polymerase; polyHEMA, polyhydroxyethylmethacrylate; Rb, retinoblastoma. Back

Received 3/12/99. Accepted 5/19/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Werb Z., Ashkenas J., MacAuley A., Wiesen J. F. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz. J. Med. Biol. Res., 29: 1087-1097, 1996.[Medline]
  2. Adams J. C., Watt F. M. Regulation of development and differentiation by the extracellular matrix. Development (Camb.), 117: 1183-1198, 1993.[Medline]
  3. Lelievre S., Weaver V. M., Bissell M. J. Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Recent Prog. Horm. Res., 51: 417-432, 1996.
  4. Hay E. D. The cell biology of the extracellular matrix Ed. 2 Plenum Publishing Corp. New York 1992.
  5. Tenniswood M. P., Guenette R. S., Lakins J., Mooibroek M., Wong P., Welsh J. E. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev., 11: 197-220, 1992.[Medline]
  6. Frisch S. M., Francis H. Disruption of epithelial cell matrix interactions induces apoptosis. J. Cell Biol., 124: 619-626, 1994.[Abstract/Free Full Text]
  7. Hynes R. O. Integrins: versatility, modulation, and signalling in cell adhesion. Cell, 69: 11-25, 1992.[Medline]
  8. Schwartz M. A., Schaller M. D., Ginsberg M. H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell. Dev. Biol., 11: 549-599, 1995.[Medline]
  9. Day M. L., Foster R. G., Day K. C., Zhao X., Humphrey P., Swanson P., Postigo A. A., Zhang S. H., Dean D. C. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J. Biol. Chem., 272: 8125-8128, 1997.[Abstract/Free Full Text]
  10. Frisch S. M., Vuori K., Ruoslahti E., Chan-Hui P. Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol., 134: 793-799, 1996.[Abstract/Free Full Text]
  11. Zhu X., Ohtsubo M., Bohmer R. M., Roberts J. M., Assoian R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E, cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol., 133: 391-403, 1996.[Abstract/Free Full Text]
  12. Raz A., Pazerini G., Carmi P. Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein. Cancer Res., 49: 3489-3493, 1989.[Abstract/Free Full Text]
  13. Lotan R., Ito H., Yasui W., Yokozaki H., Lotan D., Tahara E. Expression of a 31-kDa lactoside-binding in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int. J. Cancer, 56: 474-480, 1994.[Medline]
  14. Konstantinov K. N., Robbins B. A., Liu F-T. Galectin-3, a ß-galactoside-binding animal lectin, is a marker of anaplastic larger cell lymphoma. Am. J. Pathol., 148: 25-30, 1996.[Abstract]
  15. Nangia-Makker P., Sarvis R., Visscher D. W., Bailey-Penrod J., Raz A., Sarkar F. H. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res. Treat., 49: 171-183, 1998.[Medline]
  16. Bresalier R. S., Yan P-S., Byrd J. C., Lotan R., Raz A. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer (Phila.), 80: 776-787, 1997.[Medline]
  17. Barondes S. H., Castranovo V., Cooper D. N., Cummings R. D., Drickamer K., Feizi T., Gitt M. A., Hirabayashi J., Hughes C., Kasai K., Leffler H., Liu F. T., Lotan R., Mercurio A. M., Monsigny M., Pillai S., Poirer F., Raz A., Rigby P. W. J., Rini J. M., Wang J. L. Galectins: a family of animal ß-galactoside-binding lectins. Cell, 76: 597-598, 1994.[Medline]
  18. Yin X-M., Oltavi Z. N., Korsmeyer S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.), 369: 321-323, 1994.[Medline]
  19. Akahani S., Nangia-Makker P., Inohara H., Kim H-R. C., Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res., 57: 5272-5276, 1997.[Abstract/Free Full Text]
  20. Yang R-Y., Hsu D. K., Liu F-T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl. Acad. Sci. USA, 93: 6737-6742, 1996.[Abstract/Free Full Text]
  21. Nangia-Makker P., Thompson E., Hogan C., Ochieng J., Raz A. Induction of tumorigenicity by galectin-3 in a non-tumorigenic human breast carcinoma cell line. Int. J. Oncol., 7: 1079-1087, 1995.
  22. Lazebnik Y. A., Kaufmann S. H., Desnoyers S., Poirier G. G., Earnshaw W. C. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.[Medline]
  23. Deckwerth T. L., Johnson E. M., Jr. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J. Cell Biol., 123: 1207-1222, 1993.[Abstract/Free Full Text]
  24. Dulic V., Lees E., Reed S. I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science (Washington DC), 257: 1958-1961, 1992.[Abstract/Free Full Text]
  25. Hinds P. W., Mittnacht S., Dulic V., Arnold A., Reed S. I., Weinberg R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.[Medline]
  26. Koff A., Giordano A., Desai D., Yamashita K., Harper J. W., Elledge S., Nishimoto T., Morgan D. O., Franza B. R., Roberts J. M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (Washington DC), 257: 1689-1694, 1992.[Abstract/Free Full Text]
  27. Girard F., Strausfeld U., Fernandez A., Lamb N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell, 67: 1169-1179, 1991.[Medline]
  28. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J., 11: 961-971, 1992.[Medline]
  29. Zindy F., Lamas E., Chenivese X., Sobczak J., Wang J., Fesquet D., Henglein B., Brechot C. Cyclin A is required in S phase in normal epithelial cells. Biochem. Biophys. Res Commun., 182: 1144-1154, 1992.[Medline]
  30. Chen J., Jackson P. K., Kirschner M. W., Dutta A. Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. Nature (Lond.), 374: 386-388, 1995.[Medline]
  31. Luo Y., Hurwitz J., Massagué J. Cell cycle inhibition by independent cdk and PCNA binding domains in p21cip1. Nature (Lond.), 375: 159-161, 1995.[Medline]
  32. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin and cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.[Medline]
  33. Dowdy S. F., Hinds P. W., Louie K., Reed S. I., Arnold A., Weinberg R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73: 499-511, 1993.[Medline]
  34. Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013-1023, 1994.[Medline]
  35. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.[Free Full Text]
  36. Farquhar M., Palade G. Junctional complexes in various epithelia. J. Cell. Biol., 17: 375-412, 1963.[Abstract/Free Full Text]
  37. Nagata S. Apoptosis by death factor. Cell, 88: 355-365, 1997.[Medline]
  38. Hengartner M. O., Horvitz H. R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell, 76: 665-676, 1994.[Medline]
  39. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.[Medline]
  40. Baum L. G., Pang M., Perillo N. L., Wu T., Delegeane A., Uittenbogaart C. H., Fukuda M., Seilhamer J. J. Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells. J. Exp. Med., 181: 877-887, 1995.[Abstract/Free Full Text]
  41. Perillo N. L., Pace K. E., Seilhamer J. J., Baum L. G. Apoptosis of T cells mediated by galectin-1. Nature (Lond.), 378: 736-739, 1995.[Medline]
  42. Perillo N. L., Uittenbogaart C. H., Nguyen J. T., Baum L. G. Galectin-1, an endogenous lectin produced by thymic epithelial cells induces apoptosis in human thymocytes. J. Exp. Med., 185: 1851-1858, 1997.[Abstract/Free Full Text]
  43. Wada J., Ota K., Kumar A., Wallner E. I., Kanwar Y. S. Developmental regulation, expression and apoptotic potential of galectin-9, a ß-galactoside binding lectin. J. Clin. Invest., 99: 2452-2461, 1997.[Medline]
  44. Kadrofske M. M., Openo K. P., Wang J. L. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch. Biochem. Biophys., 349: 7-20, 1998.[Medline]
  45. Gray-Bablin J., Zalvide J., Fox M. P., Knickerbocker C. J., DeCaprio J. A., Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA, 93: 15215-15220, 1996.[Abstract/Free Full Text]
  46. Hatakeyama M., Brill J. A., Fink G. R., Weinberg R. A. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev., 8: 1759-1771, 1994.[Abstract/Free Full Text]
  47. Labaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.[Abstract/Free Full Text]
  48. Lammie G. A., Fantl V., Smith R., Schuuring E., Brookes S., Michalides R., Dickson C., Arnold A., Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to bcl-1. Oncogene, 6: 439-444, 1991.[Medline]
  49. Schuuring E., Verhoeven E., Mooi W. J., Michalides J. A. M. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene, 7: 355-361, 1992.[Medline]
  50. Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res., 52: 2980-2983, 1992.[Abstract/Free Full Text]
  51. Jiang W., Zhang Y. J., Kahn S. M., Hollstein M. C., Santella R. M., Lu S. H., Harris C. C., Montesano R., Weinstein I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-9030, 1993.[Abstract/Free Full Text]
  52. Berenson J. R., Koga H., Yang J., Pearl J., Holmes E. C., Figlin R. Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group. Oncogene, 5: 1343-1348, 1990.[Medline]
  53. Mueller A., Odze R., Jenkins T. D., Shahsesfaei A., Nakagawa H., Inomoto T., Rustgi A. K. A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res., 57: 5542-5549, 1997.[Abstract/Free Full Text]
  54. Wang L., Inohara H., Pienta K. J., Raz A. Galectin-3 is a nuclear matrix protein which binds RNA. Biochem. Biophys. Res. Commun., 217: 292-303, 1995.[Medline]
  55. Dagher S. F., Wang J. L., Patterson R. J. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc. Natl. Acad. Sci. USA, 92: 1213-1217, 1995.[Abstract/Free Full Text]
  56. Guan J-L., Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature (Lond.), 358: 690-692, 1992.[Medline]
  57. Lipfert L., Haimovich B., Schaller M. D., Cobb B. S., Parsons J. T., Brugge J. S. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J. Cell Biol., 119: 905-912, 1992.[Abstract/Free Full Text]
  58. Zhao J. H., Reiske H., Guan J. L. Regulation of the cell cycle by focal adhesion kinase. J. Cell Biol., 143: 1997-2008, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JNMHome page
S. R. Kumar and S. L. Deutscher
111In-Labeled Galectin-3-Targeting Peptide as a SPECT Agent for Imaging Breast Tumors
J. Nucl. Med., May 1, 2008; 49(5): 796 - 803.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
C Boileau, F Poirier, J-P Pelletier, M Guevremont, N Duval, J Martel-Pelletier, and P Reboul
Intracellular localisation of galectin-3 has a protective role in chondrocyte survival
Ann Rheum Dis, February 1, 2008; 67(2): 175 - 181.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
P. M. Weinberger, B.-L. Adam, C. G. Gourin, W. H. Moretz III, R. J. Bollag, B. Y. Wang, Z. Liu, J. R. Lee, and D. J. Terris
Association of Nuclear, Cytoplasmic Expression of Galectin-3 With beta-Catenin/Wnt-Pathway Activation in Thyroid Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 503 - 510.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Nakahara, V. Hogan, H. Inohara, and A. Raz
Importin-mediated Nuclear Translocation of Galectin-3
J. Biol. Chem., December 22, 2006; 281(51): 39649 - 39659.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. G. Prieto, A. A. Mourad-Zeidan, V. Melnikova, M. M. Johnson, A. Lopez, A. H. Diwan, A. J.F. Lazar, S. S. Shen, P. S. Zhang, J. A. Reed, et al.
Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma.
Clin. Cancer Res., November 15, 2006; 12(22): 6709 - 6715.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
B. Cecchinelli, L. Lavra, C. Rinaldo, S. Iacovelli, A. Gurtner, A. Gasbarri, A. Ulivieri, F. Del Prete, M. Trovato, G. Piaggio, et al.
Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis
Mol. Cell. Biol., June 15, 2006; 26(12): 4746 - 4757.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a core nutraceutical program for cancer management.
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, F. Poirier, F. P. Russo, J. P. Iredale, C. Haslett, K. J. Simpson, and T. Sethi
Galectin-3 regulates myofibroblast activation and hepatic fibrosis
PNAS, March 28, 2006; 103(13): 5060 - 5065.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Fukumori, N. Oka, Y. Takenaka, P. Nangia-Makker, E. Elsamman, T. Kasai, M. Shono, H.-o. Kanayama, J. Ellerhorst, R. Lotan, et al.
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
Cancer Res., March 15, 2006; 66(6): 3114 - 3119.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
G. A. Rabinovich, A. Cumashi, G. A. Bianco, D. Ciavardelli, I. Iurisci, M. D'Egidio, E. Piccolo, N. Tinari, N. Nifantiev, and S. Iacobelli
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis
Glycobiology, March 1, 2006; 16(3): 210 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Rennebeck, M. Martelli, and N. Kyprianou
Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis?
Cancer Res., December 15, 2005; 65(24): 11230 - 11235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Chauhan, G. Li, K. Podar, T. Hideshima, P. Neri, D. He, N. Mitsiades, P. Richardson, Y. Chang, J. Schindler, et al.
A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells
Cancer Res., September 15, 2005; 65(18): 8350 - 8358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Oka, S. Nakahara, Y. Takenaka, T. Fukumori, V. Hogan, H.-o. Kanayama, T. Yanagawa, and A. Raz
Galectin-3 Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells
Cancer Res., September 1, 2005; 65(17): 7546 - 7553.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Shalom-Feuerstein, T. Cooks, A. Raz, and Y. Kloog
Galectin-3 Regulates a Molecular Switch from N-Ras to K-Ras Usage in Human Breast Carcinoma Cells
Cancer Res., August 15, 2005; 65(16): 7292 - 7300.
[Abstract] [Full Text] [PDF]